Welcome to our dedicated page for Citrine Global news (Ticker: CTGL), a resource for investors and traders seeking the latest updates and insights on Citrine Global stock.
Citrine Global Corp. (CTGL), doing business as SkyTech Orion Global Corp., reports developments around modular small-drone systems for defense, government, and allied markets. Recent company updates center on the SkyTech Replicator™ drone platform, a modular core unit with interchangeable arms, batteries, and payloads for reconnaissance, strike, lift, logistics, and loitering missions.
Recurring disclosures also describe SkyTech Orion Ltd., the Israeli subsidiary involved in development, engineering, integration, and the SkyTech Innovation and Production Center in Israel. Company communications frame CTGL's current operating focus as a transition from plant-based wellness products toward unmanned systems, scalable manufacturing, and U.S.-Israel production infrastructure.
Citrine Global Corp. (OTCQB: CTGL), a leader in plant-based wellness solutions, recently shared a Letter to Shareholders from CEO Ora Elharar-Soffer. The company reports significant milestones since its acquisition, including the launch of the Green Side by Side product line in Q1 2022 and the acquisition of a 125,000 sq ft site for its Green Vision Center in Israel. Citrine aims to address common side effects of medications through innovative products and plans to uplist to Nasdaq, positioning itself for transformative growth in the wellness and pharma markets, expected to reach $625 billion by 2030.
Citrine Global Corp. (OTCQB: CTGL) announced the acquisition of 11,687 sqm of industrial land in Yeruham, Israel, to establish the Green Vision Center. This center aims to focus on botanical solutions, including medicinal cannabis and natural wellness products. Approximately 90% of the land acquisition costs are funded by Israeli government grants and tax incentives. The Green Vision Center will feature state-of-the-art manufacturing, research, and development facilities, furthering Citrine's mission to enhance global health through innovative wellness solutions.
Citrine Global Corp.'s subsidiary, Cannovation Center Israel Ltd., has launched its 'Green Side by Side' product line aimed at medical cannabis patients. This line features natural formulations, including oral sprays and capsules, and is marketed in collaboration with Intelicanna Ltd. in Israel. This initiative is part of Cannovation's strategy to address the increasing need for solutions to side effects from cannabis treatment, as the medical cannabis market is projected to surge to $46 billion by 2026. The company is also building a Cannovation Center for product innovation in Israel.
Citrine Global (CTGL) announced the filing of a provisional patent application for a method to treat side effects associated with cannabis use. The invention targets medical cannabis patients who often face adverse effects, with studies indicating 15% discontinue treatment despite its benefits. The medical cannabis market is expected to grow from $16 billion in 2021 to $46 billion by 2026. Citrine has developed the Green Botanicals product line to complement cannabis therapies and aims to market these supplements through established cannabis distribution channels.
Citrine Global (OTCQB: CTGL) has announced a manufacturing agreement between its subsidiary, Cannovation Center Israel Ltd., and iBOT Israel-Botanicals Ltd., to launch a new line of herbal products and supplements branded as Green Botanicals. This product line will include various herbal formulas, with plans for clinical trials on select items. The distribution strategy focuses on pharmacies and medical cannabis channels. iBOT's facility meets stringent health certifications, ensuring quality manufacturing.
Citrine Global has appointed Hagai Hillman as the CEO of Cannovation Center Israel Ltd., a majority-owned subsidiary focused on innovative health and wellness solutions, including medical cannabis. Hillman, a leader in the industry with extensive experience, will steer the center, which is supported by Israeli government grants, to become a global hub for operational innovation in the cannabis sector. The company aims to develop new products and technologies that enhance quality of life, leveraging Israel's position as a leader in high-tech and biotech markets.
Citrine Global (OTCQB: CTGL) announced the full repayment of a NIS 500 thousand loan extended to Intelicanna, including a 12% annual interest. This repayment, completed on March 31, 2021, reflects Citrine's confidence in Intelicanna, a publicly traded Israeli medical cannabis company, as it holds 619,589 shares in Intelicanna. Citrine Global is focused on health, wellness, foodtech, botanicals, and medical cannabis industries, operating through its subsidiary in Israel and planning to establish Operational Innovation Centers.
Citrine Global, Corp. (OTCQB: CTGL) has announced its application for listing on the Nasdaq Capital Market, contingent upon meeting regulatory requirements. This move aims to enhance its investor base and strengthen its brand. Additionally, on October 8, 2020, the board approved a reverse stock split, pending shareholder approval. The company focuses on innovative solutions in the healthcare and wellness sectors and operates within Israel, targeting medical cannabis and food tech.
Citrine Global, Corp. (OTCQB: CTGL) has successfully completed a share transaction with Intelicanna Ltd. (TASE: INTL), acquiring 619,589 shares valued at approximately $500,000. In exchange, Citrine Global transferred 2,143,470 shares to Intelicanna, also valued at $500,000. This strategic collaboration, initiated to support Intelicanna's growth, includes a loan and service agreement. Citrine Global aims to assist Intelicanna through ongoing financing and strategic development, while Intelicanna plans to market medical cannabis products in partnership with Neopharm Group.